| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 25.05.
| Possible Bullish Inside Day Candle Pattern Detected for Cell Therapeutics | | 2 | SmarTrend |
| 18.05.
| Recent 52-Week Low Surpassed in Shares of Cell Therapeutics | | 6 | SmarTrend |
| 11.05.
| Cell Therapeutics' Pixuvri receives European Union approval | | 6 | Pharma Bus Review |
| 11.05.
| Cell Therapeutics drug gets EU approval | | 4 | Seattle Times |
| 10.05.
| Pixuvri® von Cell Therapeutics in der Europäischen Union zugelassen zur Monotherapie mehrfach rezidivierter oder therapierefraktärer aggressiver Non-Hodgkin-B-Zell-Lymphome bei Erwachsenen | | 101 | news aktuell |
| Seattle (ots/PRNewswire) --Bedingte Zulassung beschleunigt die Verfügbarkeit einer innovativen neuen Therapie für Patienten mit einer unzulänglich behandelbaren ErkrankungSEATTLE, 10. Mai 2012 /PRNewswire/...
Mehr lesen zu:
Pixuvri® von Cell Therapeutics in der Europäischen Union zugelassen zur Monotherapie mehrfach rezidivierter oder therapierefraktärer aggressiver Non-Hodgkin-B-Zell-Lymphome bei Erwachsenen | |
| 10.05.
| Cell Therapeutics' Pixuvri® Approved in European Union as Monotherapy to Treat Adult Patients with Multiply Relapsed or Refractory Aggressive Non-Hodgkin B-Cell Lymphomas | | 34 | PR Newswire |
| - Conditional Marketing Authorization Speeds Innovative New Therapy to Patients with Unmet Medical Need
SEATTLE, May 10, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC)...
Mehr lesen zu:
Cell Therapeutics' Pixuvri® Approved in European Union as Monotherapy to Treat Adult Patients with Multiply Relapsed or Refractory Aggressive Non-Hodgkin B-Cell Lymphomas | |
| 10.05.
| Cell Therapeutics Gets Conditional European Approval For Pixuvri | | 26 | AFX News |
| WASHINGTON (dpa-AFX) - Cell Therapeutics, Inc.(CTIC) said Thursday that it
has received conditional marketing authorization from the European Commission
for Pixuvri as monotherapy for the...
Mehr lesen zu:
Cell Therapeutics Gets Conditional European Approval For Pixuvri | |
| 10.05.
| Cell Therapeutics (CTIC) Receives EU Approval for Pixuvri as Monotherapy to Treat Relapsed/Aggressive Non-Hodgkin B-Cell Lymphomas | | 2 | StreetInsider.com |
| 10.05.
| Cell Therapeutics' Pixuvri Approved in European Union as Monotherapy to Treat Adult Patients with Multiply Relapsed or Refractory Aggressive Non-Hodgkin B-Cell Lymphomas | | 2 | Benzinga.com |
| 10.05.
|
Cell Therapeutics' Pixuvri® Approved in European Union as Monotherapy to Treat Adult Patients with Multiply Relapsed or Refractory Aggressive Non-Hodgkin B-Cell Lymphomas | | 50 | PR Newswire |
| SEATTLE, May 10, 2012 /PRNewswire/ -- Cell Therapeutics, Inc.("CTI") (Nasdaq and MTA: CTIC) today announced that it has received conditional marketing authorization from the European...
Mehr lesen zu:
Cell Therapeutics' Pixuvri® Approved in European Union as Monotherapy to Treat Adult Patients with Multiply Relapsed or Refractory Aggressive Non-Hodgkin B-Cell Lymphomas | |
| 07.05.
| Possible Bullish Inside Day Candle Pattern Detected for Cell Therapeutics | | 3 | SmarTrend |
| 04.05.
| Cell Therapeutics and Savient Pharmaceuticals Look to Benefit From Shift to "First to File" Patent System / The Paragon Report Provides Stock Research on Cell Therapeutics and Savient Pharmaceuticals | | 31 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 05/04/12 -- Biotech stocks have continued to provide investors with strong gains in 2012. The iShares NASDAQ Biotechnology Index (IBB) is up nearly 20 percent year-to-date....
Mehr lesen zu:
Cell Therapeutics and Savient Pharmaceuticals Look to Benefit From Shift to "First to File" Patent System / The Paragon Report Provides Stock Research on Cell Therapeutics and Savient Pharmaceuticals | |
| 20.04.
| Cell Therapeutics Q1 12 Earnings Conference Call At 8:30 AM ET | | 64 | AFX News |
| WASHINGTON (dpa-AFX) - Cell Therapeutics Inc. (CTIC) will host a conference
call at 8:30 AM ET on April 19, 2012, to discuss Q1 12 earnings results. To access the live audio webcast, log...
Mehr lesen zu:
Cell Therapeutics Q1 12 Earnings Conference Call At 8:30 AM ET | |
| 20.04.
| Cell Therapeutics Q1 Loss Reduces | | 61 | AFX News |
| WASHINGTON (dpa-AFX) - Cell Therapeutics, Inc. (CTIC) said its first-quarter
loss attributable to CTI common shareholders narrowed to $17.45 million or $0.09
per share from $51.02 million...
Mehr lesen zu:
Cell Therapeutics Q1 Loss Reduces | |
| 20.04.
| Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones | | 62 | PR Newswire |
| SEATTLE, April 20, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (NASDAQ and MTA: CTIC) today reported financial results and recent accomplishments for the first quarter of...
Mehr lesen zu:
Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones | |
| 20.04.
| Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20 | | 51 | PR Newswire |
| SEATTLE, April 19, 2012 /PRNewswire/ -- On Friday, April 20, 2012, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s (CTI) (NASDAQ and MTA: CTIC)...
Mehr lesen zu:
Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20 | |
| 19.04.
| From Earlier: Cell Therapeutics Enters into Agreement to Acquire Pacritinib, a Novel Highly Selective JAK2 Inhibitor Phase 3 Candidate for Myelofibrosis | | 2 | Benzinga.com |
| 19.04.
| Cell Therapeutics Enters into Agreement to Acquire Pacritinib, a Novel Highly Selective JAK2 Inhibitor Phase 3 Candidate for Myelofibrosis | | 60 | PR Newswire |
| SEATTLE and SINGAPORE, April 19, 2012 /PRNewswire/ -- Cell Therapeutics, Inc.("CTI") (Nasdaq and MTA: CTIC) and S*BIO Pte Ltd announced today that the companies have entered into an asset purchase...
Mehr lesen zu:
Cell Therapeutics Enters into Agreement to Acquire Pacritinib, a Novel Highly Selective JAK2 Inhibitor Phase 3 Candidate for Myelofibrosis | |
| 19.04.
| Cell Therapeutics, Inc. (CTI) to Host Conference Call April 19, 8:30 AM ET | | 46 | PR Newswire |
| SEATTLE, April 18, 2012 /PRNewswire/ -- On Thursday, April 19, 2012, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s (CTI) (NASDAQ and MTA:...
Mehr lesen zu:
Cell Therapeutics, Inc. (CTI) to Host Conference Call April 19, 8:30 AM ET | |
| 27.03.
| Cell Therapeutics Says UW's Neuro-Oncology Program Begins Patient Enrolment | | 77 | AFX News |
| WASHINGTON (dpa-AFX) - Cell Therapeutics, Inc. (CTIC) on Tuesday said the
University of Washington's School of Medicine, Departments of Neurology and
Neurosurgery, Division of Neuro-Oncology...
Mehr lesen zu:
Cell Therapeutics Says UW's Neuro-Oncology Program Begins Patient Enrolment | |
